IndraLab
Statements
reach
"More importantly, in vivo assays further indicated that CBF could not only effectively inhibit colon tumor growth and metastasis but also significantly improve Oxa efficacy in colon tumors, which supported the promising potential of CBF as an emerging therapeutic for colon cancer.In summary, our research demonstrated that USP36 promotes the aggressiveness, chemoresistance, and metastasis of colon cancer by deubiquitinating and stabilizing c-Myc, and uncovered a potential USP36 inhibitor, CBF, in the treatment of colon cancer."